Compliance Notice from NYSE: SRx Health Solutions, Inc. received a notice from NYSE Regulation indicating non-compliance with listing standards due to the late filing of its Quarterly Report for Q2 2025.
Initial Cure Period: The company has a six-month Initial Cure Period to rectify the filing delinquency, during which the Exchange will monitor the situation and may grant an additional six months if necessary.
Company's Response: SRx is actively working with auditors to complete the Delinquent Report and aims to file it by the cure period deadline, expressing confidence in regaining compliance with listing standards.
About SRx Health Solutions: SRx is a Canadian healthcare services provider specializing in integrated specialty healthcare across all provinces, focusing on patient-centric solutions and exceeding client expectations.
SRXH
$0.3769+Infinity%1D
Analyst Views on SRXH
About SRXH
SRx Health Solutions, Inc. is a pet health and wellness company focused on providing pet products and services. The Company offers a portfolio of pet health and wellness products for dogs and cats sold under its Halo brand in multiple forms, including foods, treats, toppers, dental products, chews and supplements. Its products consist of kibble and canned dog and cat food, freeze-dried raw dog food and treats, vegan dog food and treats, oral care products and supplements. It offers products in different channels: Digital, which includes the sale of products to online retailers such as Amazon and Chewy; Brick & Mortar, which includes the sale of products to pet specialty retailers, independent pet stores, and regional distributors; and International, which includes the sale of products to foreign distribution partners and to select international retailers. The Company also operates a specialty pharmacy business through its wholly-owned subsidiary SRx Health Solutions (Canada) Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
